151 related articles for article (PubMed ID: 2147979)
1. Phenytoin potentiation of neuroleptic-induced dyskinesias.
Sethi KD; Hitri A; Diamond BI
Mov Disord; 1990; 5(4):325-7. PubMed ID: 2147979
[TBL] [Abstract][Full Text] [Related]
2. Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum.
Boyson SJ; McGonigle P; Luthin GR; Wolfe BB; Molinoff PB
J Pharmacol Exp Ther; 1988 Mar; 244(3):987-93. PubMed ID: 2908050
[TBL] [Abstract][Full Text] [Related]
3. Classification of neuroleptics: implications for tardive dyskinesia.
Christensen AV
Pol J Pharmacol Pharm; 1985; 37(3):295-309. PubMed ID: 2866499
[TBL] [Abstract][Full Text] [Related]
4. The pathophysiology of tardive dyskinesia.
Klawans HL; Carvey P; Tanner CM; Goetz CG
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):38-41. PubMed ID: 2858479
[TBL] [Abstract][Full Text] [Related]
5. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
Jeste DV; Wyatt RJ
J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
[TBL] [Abstract][Full Text] [Related]
6. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
Hess EJ; Albers LJ; Le H; Creese I
J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of dopamine supersensitivity by estrogen: neurochemical studies in an animal model of tardive dyskinesia.
Gordon JH; Diamond BI
Biol Psychiatry; 1981 Apr; 16(4):365-71. PubMed ID: 7194695
[TBL] [Abstract][Full Text] [Related]
8. Behavioral responsitivity to dopamine receptor agonists after extensive striatal dopamine lesions during development.
Neal-Beliveau BS; Joyce JN
Dev Psychobiol; 1998 May; 32(4):313-26. PubMed ID: 9589220
[TBL] [Abstract][Full Text] [Related]
9. Cyclo (Leu-Gly) attenuates the striatal dopaminergic supersensitivity induced by chronic morphine.
Lee JM; DeLeon-Jones F; Fields JZ; Ritzmann RF
Alcohol Drug Res; 1987; 7(1):1-10. PubMed ID: 2431697
[TBL] [Abstract][Full Text] [Related]
10. Neuroleptic drugs and their action on different neuronal pathways.
Ungerstedt U; Herrera-Marschitz M; Forster C
J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):34-7. PubMed ID: 2858478
[TBL] [Abstract][Full Text] [Related]
11. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation.
Darmopil S; Martín AB; De Diego IR; Ares S; Moratalla R
Biol Psychiatry; 2009 Sep; 66(6):603-13. PubMed ID: 19520364
[TBL] [Abstract][Full Text] [Related]
12. Electron spin resonance spectroscopy reveals alpha-phenyl-N-tert-butylnitrone spin-traps free radicals in rat striatum and prevents haloperidol-induced vacuous chewing movements in the rat model of human tardive dyskinesia.
Rogoza RM; Fairfax DF; Henry P; N-Marandi S; Khan RF; Gupta SK; Mishra RK
Synapse; 2004 Dec; 54(3):156-63. PubMed ID: 15452862
[TBL] [Abstract][Full Text] [Related]
13. Loss of D1/D2 dopamine receptor synergisms following repeated administration of D1 or D2 receptor selective antagonists: electrophysiological and behavioral studies.
Hu XT; White FJ
Synapse; 1994 May; 17(1):43-61. PubMed ID: 7913772
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy.
Bitton V; Melamed E
J Clin Psychiatry; 1984 Jan; 45(1):28-30. PubMed ID: 6141157
[TBL] [Abstract][Full Text] [Related]
15. Animal models for tardive dyskinesia: effects of thioridazine.
Sayers AC; Bürki HR; Ruch W; Asper H
Pharmakopsychiatr Neuropsychopharmakol; 1977 Sep; 10(5):291-5. PubMed ID: 616929
[TBL] [Abstract][Full Text] [Related]
16. Behavioral sensitization to different dopamine agonists in a parkinsonian rodent model of drug-induced dyskinesias.
Delfino MA; Stefano AV; Ferrario JE; Taravini IR; Murer MG; Gershanik OS
Behav Brain Res; 2004 Jul; 152(2):297-306. PubMed ID: 15196797
[TBL] [Abstract][Full Text] [Related]
17. PHNO, a novel dopamine agonist, in animal models of parkinsonism.
Koller W; Herbster G; Gordon J
Mov Disord; 1987; 2(3):193-9. PubMed ID: 2904649
[TBL] [Abstract][Full Text] [Related]
18. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
[TBL] [Abstract][Full Text] [Related]
19. Attenuation by pergolide of haloperidol-induced striatal dopamine receptor density.
Koller WC
J Clin Psychopharmacol; 1984 Dec; 4(6):343-5. PubMed ID: 6512004
[TBL] [Abstract][Full Text] [Related]
20. [Behavioral pharmacological investigation and clinical consideration of the inhibitory potencies of psychotropic drugs against the D-1 and D-2 dopamine receptors].
Kazawa T
Yakubutsu Seishin Kodo; 1986 Sep; 6(3):327-37. PubMed ID: 2949452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]